Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped

T. Rispens, A. Vennegoor, G.J. Wolbink, C.H. Polman, J. Killestein

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)899-901
JournalMultiple Sclerosis
Volume18
Issue number6
DOIs
Publication statusPublished - 2012

Cite this

@article{798b270649b945a390a987827870ebce,
title = "Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped",
author = "T. Rispens and A. Vennegoor and G.J. Wolbink and C.H. Polman and J. Killestein",
year = "2012",
doi = "10.1177/1352458511431073",
language = "Undefined/Unknown",
volume = "18",
pages = "899--901",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "6",

}

Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped. / Rispens, T.; Vennegoor, A.; Wolbink, G.J.; Polman, C.H.; Killestein, J.

In: Multiple Sclerosis, Vol. 18, No. 6, 2012, p. 899-901.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped

AU - Rispens, T.

AU - Vennegoor, A.

AU - Wolbink, G.J.

AU - Polman, C.H.

AU - Killestein, J.

PY - 2012

Y1 - 2012

U2 - 10.1177/1352458511431073

DO - 10.1177/1352458511431073

M3 - Article

VL - 18

SP - 899

EP - 901

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

IS - 6

ER -